Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Biotech Investors Luncheon 2022
31 slides from Genetic Technologies's conference presentation, May 16, 2022
Slide 1: ASX Market Announcement: Biotech Investors Luncheon
ASX Market Announcement For personal use only Biotech Investors Luncheon – Emerging Biotech Conquering Global Markets Melbourne, Australia, 16 May 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE), Medlab Clinical Ltd (ASX: MDC) and Recce Pharmaceuticals (ASX: RCE) are pleased to be joinin
Slide 2: About Recce Pharmaceuticals and contacts
About Recce Pharmaceuticals Recce Pharmaceuticals is pioneering the development and commercialisation of a New Class of Synthetic Anti- Infectives designed to address the urgent global health threat posed by antibiotic-resistant superbugs and emerging viral pathogens. For more information, please vi
Slide 3: Introduction to GeneType
For personal use only Introduction to GeneType Biotech Investors Luncheon May 16, 2022 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 4: Notice: Forward looking statements
For personal use only Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they
Slide 5: Our Overview
Our Overview For personal use only Our Vision Our Portfolio & Innovation Unlocking personalised preventative health Cutting edge technology & ‘game changing’ partnerships Our Global Presence Our Channels & Divisions Expansion to over 40 countries Segmentation and distribution channels Our Market Opp
Slide 6: Genetype Vision
For personal use only Genetype Vision 4
Slide 7: Unlocking personalised preventative health
Unlocking personalised For personal use only preventative health Our Mission Transform the conversation, transitioning from a one-size-fits-all model to personalised, predictive health assessment – where each person has the information, they need to manage their health according to their own risk. B
Slide 8: Patented integrated risk testing for a range of serious conditions
Patented integrated risk testing for a range For personal use only of serious conditions. Genetype tests integrate individual’s familial, clinical and genetic information into actionable clinical insights. Combining genetic and clinical risk models with cutting-edge research, we’re leading a persona
Slide 9: Our Global Presence
Our Global Presence For personal use only 54 40 27 Employees Countries Patents globally Granted (9 Pending) 14 51 12 Test Tests Partner Categories Laboratories 7 7
Slide 10: Key Geographies and Collaborators
Key Geographies and Collaborators For personal use only Genetype and EasyDNA Established in 40 countries with 12 established partnerships United States Europe & UK Asia Australia & New (Inc. SEA, China and India) Zealand geneType® Polygenic Risk EasyDNA available in EasyDNA available in Certificatio
Slide 11: Our Market Opportunity
Our Market Opportunity Estimated Global Revenue growth is USD$2.8B in to 2025 For personal use only CAGR 16.3% Predictive Genomics1 Growth $1.3B Direct to Consumer2 CAGR 18.1% Growth $1.4B 2.01 2025 0.76 2.60 2020 1.22 USD ($B) USD ($B’m) 1. Newsire - Predictive Genetics Market Research Report by Ty
Slide 12: Our Innovation
For personal use only Our Innovation Product Overview 10 10
Slide 13: Divisions of Operations
Divisions of Operations For personal use only NEW Existing divisions Universal Pharmoco- collection test kit Oncology Genetics & Emerging divisions BC, CRC, PC, Taliaz to support Multi Melanoma Companion Test Launch diagnostics Germline CVD testing (Heart Disease) BRCA, Lynch IHD, AF Syndrome and So
Slide 14: Our latest Innovation – Multi-Risk Test
Our latest Innovation – Multi- Risk Test A companion diagnostic PRS to help identify risk of serious disease for up to 70% of For personal use only Mortalities and Morbidities and save payors GeneType Multi- test to include >70% of mortality Diseases Areas & morbidity Oncology Cardiovascular Breast
Slide 15: Integrated personalised risk assessment
Integrated personalised risk assessment For personal use only geneType integrates genetic risk and clinical risk to better stratify individual risk. Patients with potentially high risk may exceed actionable clinical guidelines 10 – 15 years earlier than those with low risk 1,2,3 Breast Cancer (BC)1
Slide 16: Economic Modeling in the US Payor System
Economic Modeling in the US Payor System1 Equates to 3.6% in annual savings to a payor system in the screening and For personal use only treatment of breast cancer. Annual Payor Net Savings per Patient Tested $73 69% - 74% 6.8%-9.2% Excludes Cost of GTG Test Treatment & Screening Costs Only $90 US P
Slide 17: Pathways to Market
Pathways to Market For personal use only Direct to Consumer Consumer initiated Medical Business to Testing (DTC) testing (CIT) Business (B2B) with no medical supervision with medical supervision Revenue Leveraging the EasyDNA Brand and Health Economic modeling being Drivers Building consumer Awarene
Slide 18: Pathways to Market: multi-brand strategy
Pathways to Market Executing a multi-brand strategy For personal use only 1 Direct to consumer [insert revenue structure and agreement Ancestry Animaltypes] Paternity Drug testing Product list Health & Wellbeing Relationship Pharmacogenetics Consumer-initiated testing 2 ± telehealth support [insert
Slide 19: Key Operating Insights
For personal use only Key Operating Insights 17 17
Slide 20: Delivering Revenue and Growth YTD March FY22
Delivering Revenue and Growth YTD March FY22 For personal use only Revenue (A$'000) $5,610 REVENUE YTD CASH BALANCE AUD $5.6m AUD $11.3m* half-year ending December 31, 2021 $2,338 GROSS MARGIN YTD GROSS MARGIN YTD $25 $781 Q3 FY21 Q3 FY22 YTD March FY21 YTD March FY22 AUD $2.9m 52.1% Strategic & Ope
Slide 21: Corporate Overview
Corporate Overview For personal use only Top 50 share registry breakdown BNY Mellon Board & Management Other Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 19 April 2022 0.4c Other, 24% ADR price (USD) as at 19 April 2022 $1.85 Ord Shares on Issue (M) 9,234 Board & A
Slide 22: Financial Overview
Financial Overview For personal use only • Cash burn of A$2.1 million in Q3 FY’22 (compared to Q2 FY’22: A$2.2 million) as we continue to grow EasyDNA brand sales and develop and commercialize our geneType tests A$’000 31-Dec-21 31-Mar-22 Change • Cash reserves of A$11.4 million after EasyDNA acquis
Slide 23: Summary
For personal use only Summary 21
Slide 24: Snapshot and Achievements
Snapshot and Achievements For personal use only Signed multi-year distribution Acquired revenue generating Focused on R&D collaborations agreement platform and Innovation ✓ License and distribution agreement for ✓ Showing solid Quarter on Quarter ✓ African American Breast Cancer Research COVID-19 Ri
Slide 25: Commercialisation of the geneType suite of multi-risk tests
For personal use only Commercialisation of the geneType suite of multi-risk tests EasyDNA Growth: New Test. New Channels. New Markets. Our6 Demonstrate clinical validity & clinical utility of geneType tests Areas Bolster commercial bias to our OPEX Talent & capability acquisition Innovation: Gene Ve
Slide 26: Thank you
For personal use only Thank you Investor Relations Hugh Morgan Market Eye +61 407453 109 hugh.morgan@marketeye.com.au 24
Slide 27: Appendices
For personal use only Appendices 25
Slide 28: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board For personal use only Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. A.Prof Ron Dick MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MD, MS, FACMG MBBS, FRACP, FCSANZ, Research & Education Lead, MWGO is Principal Fellow and Reg
Slide 29: Our Intellectual Property
Our Intellectual Property For personal use only 8 Patents granted in the US 9 Patent families pending • Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection • Methods for breast cancer risk • Patent 11,031,098, Computer systems and methods for
Slide 30: Board and Management
Board and Management: Sales and Scientific expertise leading GTG For personal use only Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Com, FAICD, FCA, Chairman - Non – Non – Executive FGIA, FTIA, F Fin Executive Director Director Non – Executive Director Dr. Jerzy “George
Slide 31: Defined Terms
Defined Terms For personal use only Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score
Genetic Technologies — Biotech Investors Luncheon 2022 on 6ix